The table below shows Vaxcyte, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$655.58M
-$452.63M
-$296.79M
-$170.60M
-$121.39M
-$46.63M
Capital expenditure
$13.71M
$22.43M
$16.06M
$5.84M
$6.55M
$1.16M
Investing cash flow
$437.35M
-$2.01B
-$773.31M
$74.58M
-$212.31M
-$1.10M
Dividends paid
-
-
-
-
PCVX operating cash flow (10-K history)
Vaxcyte, Inc. reported operating cash flow of -$655.58M for fiscal year 2025. That is down 44.8% from -$452.63M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$30.47M (FY 2018) to -$655.58M. Figures come from the company's audited annual reports as filed with the SEC.